French National Observatory of Patients With Thymic Epithelial Tumor

Thymic Epithelial Tumor Clinical Trial

— RYTHMIC  

Official title:

French National Observatory of Patients With Thymic Epithelial Tumor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02724696
• Other study ID #: IFCT-1104 RYTHMIC
• Status: Recruiting
• Start date: January 2012
• Est. completion date: December 2025

Study information

• Verified date: May 2023
• Source: Intergroupe Francophone de Cancerologie Thoracique
• Contact: Franck Morin
• Email: contact[@]ifct.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French nationwide network for TET with the objective of territorial coverage by regional expert centers and systematic discussion of patients management at national tumor board.

Description:

RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a nationwide network for TET appointed in 2012 by the French National Cancer Institute. The objectives of the network are management of clinical tumor boards and central pathologic review of all cases. RYTHMIC Tumor Board is based on initial histopathological diagnosis.

RYTHMIC is a comprehensive tool for research:

• to improve the management of patients

• to monitor dedicated actions

• to screen patients for future translational and clinical trials

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3262
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patient with Thymic Epithelial Tumors

Exclusion Criteria:

• histology other than Thymic Epithelial Tumors

Related Conditions & MeSH terms

• Neoplasms, Glandular and Epithelial
• Thymic Epithelial Tumor
• Thymus Neoplasms

Locations

Country	Name	City	State
France	Paris - Institut Curie	Paris
France	Villejuif - Institut Gustave Roussy	Villejuif

Sponsors (1)

Lead Sponsor	Collaborator
Intergroupe Francophone de Cancerologie Thoracique

Country where clinical trial is conducted

France, 

References & Publications (17)

Basse C, Botticella A, Molina TJ, Falcoz PE, Oulkhouir Y, Kerjouan M, Pichon E, Westeel V, Thiberville L, Quantin X, Clement-Duchene C, Khalifa J, Tinier FL, Ginoux M, Thillays F, Mordant P, Besse B, Thomas PA, Pechoux CL, Girard N. RADIORYTHMIC: Phase II — View Citation

Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, Massabeau C, Clement-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, Girard N. Multidis — View Citation

Benitez JC, Boucher ME, Dansin E, Kerjouan M, Bigay-Game L, Pichon E, Thillays F, Falcoz PE, Lyubimova S, Oulkhouir Y, Calcagno F, Thiberville L, Clement-Duchene C, Westeel V, Missy P, Thomas PA, Maury JM, Molina T, Girard N, Besse B. Central Nervous Syst — View Citation

Chalabreysse L, Dubois R, Hofman V, Le Naoures C, Mansuet-Lupo A, de Montpreville VT, De Muret A, Parrens M, Piton N, Rouquette I, Secq V, Singeorzan C, Marx A, Girard N, Besse B, Molina TJ. [Thymoma and squamous thymic carcinoma diagnosis; experience fro — View Citation

Chalabreysse L, Thomas De Montpreville V, De Muret A, Hofman V, Lantuejoul S, Parrens M, Payan MJ, Rouquette I, Secq V, Girard N, Marx A, Besse B, Molina TJ. [Rythmic-pathology: the French national pathology network for thymic epithelial tumours]. Ann Pat — View Citation

Drevet G, Collaud S, Tronc F, Girard N, Maury JM. Optimal management of thymic malignancies: current perspectives. Cancer Manag Res. 2019 Jul 22;11:6803-6814. doi: 10.2147/CMAR.S171683. eCollection 2019. — View Citation

Girard N, Merveilleux Du Vignaux C, Molina T, Besse B, Rythmic R. [Thymic tumors]. Rev Prat. 2017 Apr;67(4):430-434. French. — View Citation

Hadoux J, Girard N, Besse B. [Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France]. Bull Cancer. 2012 Nov;99(11):1045-55. doi: 10.1684/bdc.2012.1659. French. — View Citation

Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazieres J, Besse B, Girard N. Systemic The — View Citation

Molina TJ, Bluthgen MV, Chalabreysse L, de Montpreville VT, de Muret A, Dubois R, Hofman V, Lantuejoul S, le Naoures C, Mansuet-Lupo A, Parrens M, Piton N, Rouquette I, Secq V, Girard N, Marx A, Besse B. Impact of expert pathologic review of thymic epithe — View Citation

Noel N, Le Roy A, Hot A, Saadoun D, Lazaro E, Levesque H, Le Gouellec N, Meaux-Ruault N, Nguyen T, Costedoat-Chalumeau N, Amieux B, Fontana A, De Gennes C, Fulpin J, Thomas PA, Bluthgen MV, Besse B, Lambotte O. Systemic lupus erythematosus associated with — View Citation

Petat A, Dansin E, Calcagno F, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Thillays F, Quantin X, Oulkhouir Y, Thiberville L, Ricordel C, Thomas De Montpreville V, Chalabreysse L, Hofman V, Molina T, Fournel P, Bigay Game — View Citation

Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B. Erratum to "Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network" [Lung Cancer, 97 (July 2016), 99-104]. Lung Cancer. — View Citation

Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. Lung Cancer. 2016 Jul;97:99-104. doi: 10.1016/j.lungcan.2016.04. — View Citation

Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen MV, Perallon R, Chalabreysse L, De Muret A, Hofman V, Marx A, Parrens M, Secq V, Thomas de Montpreville V, Galateau-Salle F, Brousset P, Milia J, Girard N, Besse B, Molina TJ, Mazieres J. Immune biom — View Citation

Thomas de Montpreville V, Mansuet-Lupo A, Le Naoures C, Chalabreysse L, De Muret A, Hofman V, Rouquette I, Piton N, Dubois R, Benitez JC, Girard N, Besse B, Marx A, Molina TJ. Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohis — View Citation

Thomas de Montpreville V, Quilhot P, Chalabreysse L, De Muret A, Hofman V, Lantuejoul S, Parrens M, Payan MJ, Rouquette I, Secq V, Girard N, Besse B, Marx A, Molina TJ. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive — View Citation

* Note: There are 17 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	histological type	histological type according to the WHO classification 2004/2015	5 years
Primary	Masaoka-Koga stage	Masaoka-Koga stage	5 years
Primary	ITMIG/IASLC 2014/2015 stage	ITMIG/IASLC 2014/2015 stage	5 years
Secondary	Questions raised at the national expert multidisciplinary tumor board	Diagnosis/Imaging, Surgery, Chemotherapy, Radiotherapy	5 years